From 10th until 12th of Fabruary 2016 will take place a “Course for health care guidelines developers on treatments of rare diseases” in Milan, Italy. The present course is part of the project RARE-Bestpractices and intends to promote guideline quality standards for rare diseases across Europe. The course will provide participants with the opportunity to acquire skills necessary to produce health care guidelines on treatments of rare diseases. For more information and registration, please check the programme of the course and the RARE-Bestpractices project website .
admin
Folia Medica Journal has published a paper on the economic burden and health-related quality of life (HRQOL) of patients with cystic fibrosis (CF). The study within the European project BURQOL-RD included 33 patients with CF and 17 caregivers from Bulgaria. Median annual costs of CF in Bulgaria were € 24 152 per patient in 2012 as a reference year. Median annual costs in children were found to be significantly higher than those in adults – € 31 945 vs. € 15 714. This outcome came from statistically significant differences in costs for main informal carer and costs for other informal carers. Median annual drug costs were € 13 059. Bulgarian CF patients indicated lowered HRQOL results – 50.00 median VAS score. The full-text article is available here.
6th National Conference for Rare Diseases and Orphan Drugs proceedings book is now published on our website. You can explore all the presentations and posters (in Bulgarian). The e-book can be downloaded from here. The Institute for Rare Diseases would like to thank all conference speakers and participants.
The Institute for Rare Diseases and the Faculty of Public Health at the Medical University of Plovdiv are organising a health technology assessment workshop, which will be held on 17-18 October 2015 at the Ramada Plovdiv Trimontium Hotel in Plovdiv.
Funding of treatment with innovative therapies in Bulgaria is expected to undergo substantial changes in 2016. In this context, the training seminar aims to build up understanding of the role of health technology assessment and different tools for access to innovative therapies. Leading British experts will discuss patient access schemes in the UK. Paul Kind, a Professor of Health Outcome Measurement in the Academic Unit of Health Economics within the Leeds Institute of Health Sciences will be a keynote speaker. Professor Kind is a founder member and past-President of the EuroQoL Group, a multinational research cooperative responsible for the development of EQ-5D and currently serves as a member of its Scientific Executive. For further information and registration, please contact info@raredis.org.
The official programme of the 6th National Conference on Rare Diseases and Orphan Drugs is now available. 8 plenary sessions and 1 poster session will present the recent innovations in the personalised approach to rare diseases. Session topics include expert centres and reference networks for rare diseases, personalised health care to patients with rare disease, registries and health technology assessment for rare diseases. For more information, please visit the official website of the event.
National alliance of people with rare diseases is organizing a training workshop “Self-help Practises for Improving Quality of Life in Rare Diseases”. Lecturers will be Poli Paskova, Dr. Marieta Zheleva, Miaria Anastasova, Elena Leseva and Elena Eneva. Participants will have the opportunity to take valuable advises, to discover the possibilities of alternative self-help techniques and how best to use them. The seminar will be held on 10-11 October 2015 in Hotel “Rusalka”, Plovdiv. To read the preliminary programme (in Bulgarian), please click here. For further information, please contact Ms. Yordanka Petkova, co-ordinator of NAPRD.
The Commission on Rare Diseases at the Ministry of Health adopted an official proposal form for inclusion of diseases into the Bulgaria’s List of Rare Diseases, as well as an official request form for designation of an expert centre for rare diseases.
The Commission on Rare Diseases was established by the Minister of Health in implementation of Ministerial Ordinance № 16 of July 30, 2014 on the terms and conditions for registration of rare diseases and designation of centres of expertise and reference networks for rare diseases. The Commission prepares opinions to the Minister of Health on proposals for inclusion in the List of Rare Diseases, as well as makes proposals to the Director of National Centre for Public Health for designation of centres of expertise and reference networks for rare diseases.
The submission of proposals for inclusion of diseases into the List of Rare Diseases and requests for designation of expert centre for rare diseases is ongoing and in accordance with the procedures under Ordinance № 16. The official forms in doc and pdf formats can be downloaded from here.
Based on the evidence from the new study, a theoretical framework of a budget impact study for RD is proposed:
- A retrospective analysis could provide essential health policy insights in terms of impact on accessibility and population health, which are significant benchmarks in shaping funding decisions in healthcare.
- Budget impact studies are recommended to focus on RD rather than orphan drugs (OD). In policy context, RD are the public health priority. OD is a dynamic characteristic and compromises the consistency and comparability of the calculated budget indicators.
You can read the full text here.
European Commission published an evaluative study, carried out in 12 EU countries regarding the implementation of the Directive for cross-border healthcare.
The main stakeholders involved were the National Contact Points, healthcare provider organisations, individual health insurance providers, patient groups, trade unions, ombudspersons and healthcare inspectorate /audit bodies.
The main findings of the study are systemized in three major issues: Reimbursement, Quality and Safety, and Undue Delay:
- There is a small number of reimbursement requests due to lack of awareness for the possibilities and the small number of information requests received by National Contact Points.
- Patients don’t seek information about quality and security of treatment in advance and often request necessary information subsequent to their choice of healthcare unit.
- Websites of governments or health insurance providers often disclose information on the average waiting times for different treatments.
The major outcome of the study is that the Directive is at an early stage of implementation. A larger awareness campaign is needed about the opportunities it offers to the patients.
You can read the full Executive summary here.
DG Health and Food Safety is organising the “2nd conference on European Reference Networks” on 8-9 October 2015 in Lisbon, Portugal. This conference will bring together highly specialised healthcare providers, experts, national authorities, decision–makers, and independent bodies with experience in the assessment and evaluation of healthcare providers.
This 2nd conference is hosted by the Ministry of Health of Portugal and supported by the Luxembourgish EU Presidency. The conference will focus on the implementation of European Reference Networks and facilitate the exchange of information and expertise on establishing and evaluating such Networks. It will look into the next steps of the deployment process, in preparation for the forthcoming call for European Reference Networks in 2015.
Establishing European Reference Networks, in accordance with Directive 2011/24/EU on the application of patients’ rights in cross-border healthcare, of highly specialised healthcare providers represents a clear added value for the EU and will help to provide affordable, high-quality and cost-effective healthcare to patients with conditions requiring a particular concentration of resources or expertise. It intends to improve these patients’ access to the best possible expertise and care available in the EU for their condition.
There will be more information soon on EU website.